Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature

Mediators Inflamm. 2015;2015:792173. doi: 10.1155/2015/792173. Epub 2015 Mar 26.

Abstract

Background: There are few data on anakinra use after failure of conventional medications for crystal-induced peripheral arthritis and/or crowned dens syndrome among complex hospitalized patients.

Methods: We retrospectively analyzed the outcome of six patients affected with subacute crystal-induced arthritis who had received anakinra in second or third line therapy, including three patients with crowned dens syndrome and three others with gouty arthritis. Patients' comorbidities, reasons for anakinra use and associated drugs, and outcomes were recorded.

Results: All patients presented with elevated inflammatory syndrome, systemic symptoms with poly/oligoarthritis. Except for absolute contraindications, all patients were previously treated with full or decreased dose of NSAID, colchicine, and/or glucocorticoids, with unsatisfactory response. All three gouty patients exhibited complete responses in all acute involvements under anakinra within 3 to 5 days, including one of them who needed the reintroduction of colchicine treatment that was previously unsuccessful. Crowned dens syndrome patients, including two with pseudogout and one with subacute hydroxyapatite deposition disease, needed 9 to 11 days to achieve complete response. Tolerance to anakinra was good.

Conclusion: In case series of complex hospitalized patients, anakinra showed good activity in crowned dens syndrome and associated crystal-induced peripheral arthritis, with longer treatment duration than in gouty arthritis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Arthritis / drug therapy*
  • Arthritis, Gouty / drug therapy*
  • C-Reactive Protein / metabolism
  • Colchicine / therapeutic use
  • Comorbidity
  • Female
  • Glucocorticoids / therapeutic use
  • Hospitalization
  • Humans
  • Inflammation / drug therapy
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Male
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antirheumatic Agents
  • Glucocorticoids
  • Interleukin 1 Receptor Antagonist Protein
  • C-Reactive Protein
  • Colchicine